Objectives. We set out to identify randomized controlled trial (RCT) evidence for the effectiveness of oral versus intramuscular vitamin B 12 to treat vitamin B 12 deficiency. Methods. We conducted a systematic review searching databases for relevant RCTs. Outcomes included levels of serum vitamin B 12 , total serum homocysteine and methylmalonic acid, haemoglobin and signs and symptoms of vitamin B 12 deficiency.
Introduction
Vitamin B 12 deficiency is common; prevalence estimates among the general population range from 1.5 to 15%. [1] [2] [3] [4] Adequate treatment is essential as vitamin B 12 is necessary for the development of red blood cells, normal growth and nervous system maintenance. Vitamin B 12 deficiency causes anaemia, fatigue, mood disturbance and other neuropsychiatric and neurological complications. Vitamin B 12 deficiency has also been linked with an increased risk of myocardial infarction and stroke. 5 Vitamin B 12 is absorbed in the terminal ileum. This absorption is almost entirely dependent upon intrinsic factor (IF). The most common, non-dietary cause of vitamin B 12 deficiency is autoimmune pernicious anaemia. Other common causes include gastrectomy, ileal resection, pancreatic insufficiency and malabsorption syndromes such as Crohn's disease and coeliac disease. Less common causes include use of drugs such as metformin and proton pump inhibitors, and rarely malabsorption due to gastrointestinal bacterial overgrowth and infestation.
Vitamin B 12 was first isolated in its cyano-form in 1948, 6, 7 and is now widely used for the treatment of vitamin B 12 deficiency. Most B 12 -deficient individuals are treated with intramuscular vitamin B 12 . Intramuscular injections are a 'considerable source of work' for health care professionals, 8 and can be painful. 9 While serious adverse reactions are rare, injections can be dangerous in anticoagulated patients. There is little difference in the cost of oral versus intramuscular therapy when medication alone is considered. However, intramuscular administration often involves a trip to a health facility or a home visit by a health professional to administer the injection. 10 Effective oral treatment could therefore save considerable health service resources by reducing contacts with health personnel. 11 Several case-control and case series studies have suggested equal efficacy of the oral route. [12] [13] [14] The mechanism for this oral route is most probably that free vitamin B 12 can be absorbed both passively (without binding to IF) as well as actively (following binding to IF) in the terminal ileum. Passive diffusion accounts for 1-2% of total absorption and is unaffected in patients with pernicious anaemia or gastro-duodenal surgical resection. 15, 16 Vitamin B 12 is rarely prescribed in the oral form in most countries, other than Canada and Sweden, where such replacement recently accounted for 73% of the total vitamin B 12 prescribed. 17 Possible reasons for doctors not prescribing oral formulations include unawareness of this option or concerns regarding effectiveness due to unpredictable absorption. 10, 18 In view of international variations in practice and the considerable resource implications associated with the choice of route for replacement therapy, we conducted a systematic review of randomized controlled trials (RCTs) evaluating vitamin B 12 replacement using oral vitamin B 12 .
A more detailed review has been published in The Cochrane Database of Systematic Reviews.
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Methods
We considered published and unpublished RCTs providing evidence for the effectiveness of oral vitamin B 12 to treat vitamin B 12 deficiency in participants with low serum vitamin B 12 levels. We used a cut-off point of 180 pmol/l (or 240 pg/ml) as threshold serum level for vitamin B 12 deficiency. We considered studies comparing oral vitamin versus intramuscular vitamin B 12 .
We excluded studies evaluating vitamin B 12 in the prevention of cardio-vascular diseases because the dose of vitamin B 12 used in these studies is generally much smaller compared with doses used to treat vitamin B 12 deficiency and the vast majority of patients included in these studies are not vitamin B 12 deficient. We also excluded studies of patients with primary folate deficiency (because the concomitant use of folate would confound the metabolic outcome measures), and studies of patients with end-stage renal disease or on haemodialysis (because renal disease would also confound the metabolic outcome measures). We planned to note whether included patients suffered from conditions associated with gut malabsorption.
Our main outcome measure was serum vitamin B 12 levels. Additional outcome measures were serum homocysteine and methylmalonic acid levels, haemoglobin and mean corpuscular volume (MCV), clinical signs and symptoms of vitamin B 12 deficiency, costs, adverse effects, acceptability to patients and quality of life.
We ). Our search strategy was based on the strategy described in the Cochrane Reviewers' Handbook (Optimal Search Strategy for RCTs). We used it in conjunction with the terms 'pernicious anaemia' and 'vitamin B 12 deficiency' for searches of Medline Ovid Web, and adapted it slightly for other electronic databases. The search strategy is available as Supplementary Data on the journal's website www.fampra.oxfordjournals.org. The bibliographies of all relevant papers identified by this strategy were searched for additional studies. We contacted the authors of relevant studies, experts in the field and manufacturers of oral and intramuscular preparations of vitamin B 12 to enquire about additional published or unpublished studies, ongoing trials and to obtain additional references.
All abstracts or titles identified by the electronic searches were independently scrutinized by two researchers. When uncertainty arose, or when there were differences between these reviewers, hard copies of papers were obtained and reviewed and decisions made by consensus. The group checked whether inclusion and exclusion criteria were met; disagreement was resolved by consensus.
We obtained a copy of all selected papers, and two researchers independently extracted data using piloted data extraction forms. We used the scheme described in the Cochrane Collaboration Handbook for assessing methodological quality. This scheme uses the criteria specified by Schulz and by Jadad 20, 21 and involves assessing studies for publication, selection, performance, attrition and detection bias. Based on these criteria a 3-point rating scale was used, with the following grading: A-all quality criteria met: low risk of bias (plausible bias is unlikely to alter the results seriously); B-one or more of the quality criteria only partly met: moderate risk of bias (plausible bias raises some doubt about the results) and C-one or more criteria not met: high risk of bias (plausible bias seriously weakens confidence in the results).
The methodological quality of the included studies was independently assessed by two researchers and disagreements brought back to the whole group for resolution by consensus.
Results
Final searches were performed in early 2005. After manually removing all duplicates, we pre-selected 797 abstracts. After scrutiny of these, we obtained the full paper for 42 studies. Two studies met the inclusion criteria. We identified another 15 studies through searching bibliographies of selected articles and other relevant studies, and obtained the full text for these additional studies. These were mainly from the 1950s and early 1960s. A total of 57 studies were thus selected for review of the full paper. Most publications were written in English (88%), but we found seven papers that we felt warranted closer scrutiny written in other languages (Italian, French, Danish and Czech).
Fifty-five studies were excluded. The most common reason for exclusion was a non-randomized trial design (58%) or the study did not meet intervention criteria (32%).
Two RCTs 22,23 fulfilled our inclusion criteria. Two groups of researchers independently extracted data from these reports using piloted data extraction forms. We did not extract data from non-randomized studies or studies that clearly did not meet the inclusion criteria. The whole group checked all the relevant studies in relation to inclusion and exclusion criteria. Characteristics of these studies are shown in the ' Table of Included Studies' (Table 1) .
Description of included studies
Two studies compared oral administration of vitamin B 12 versus intramuscular administration of vitamin B 12 . 22, 23 Participants in both studies had low serum vitamin B 12 levels and both were set in outpatient hospital clinics. The first study was carried out in USA by Kuzminski and colleagues, 23 and the second in Turkey by Bolaman and colleagues. 22 Kuzminski and colleagues recruited 38 patients with a mean age of 72 years (for those randomized to oral treatment) and 71 years (for those randomized to intramuscular treatment) and followed 33 of them up for 4 months. Twenty-eight of these patients had conditions that may be associated with malabsorption from the gut (including seven with pernicious anaemia and three with ileal resection), although patients with inflammatory bowel disease and coeliac disease appear not to have been included. Bolaman and colleagues recruited 70 patients with a mean age of 60 years for the oral group and 64 years for the intramuscular group and followed 60 of them up for 90 days. Thirty-five of these patients had conditions affecting the ileum that may be associated with malabsorption from the gut. Again, however, patients with inflammatory bowel disease and coeliac disease appear not to have been included. The dose of oral vitamin B 12 used by Kuzminski and colleagues was 2000 mg; 23 Bolaman and colleagues used 1000 mg. 22 The dose of intramuscular vitamin B 12 was 1000 mg in both studies. 22, 23 Bolaman and colleagues 22 used the 'block randomization method' described by Altman. 22, 24 We considered the block randomization a satisfactory method for removing bias from the allocation procedure if applied correctly. Kuzminski and colleagues 23 used a 'Statistical Analysis System' for randomization but did not provide further details and did not describe attempts to conceal the assignment of participants. Neither study reported a sample size calculation. Patients in both studies knew whether they were taking oral or intramuscular medication, since no placebo was used.
We considered the length of follow-up in these studies insufficient because of the long biological half-life of body stores of vitamin B 12 . This is estimated to be more than 480 days. 25 Further details of the methodological quality of the included studies can be found in Table 2 .
Effect of interventions
In the study by Kuzminski and colleagues, 23 mean serum vitamin B 12 levels were significantly higher in the oral (643 ± 328 pg/ml; n = 18) compared with the intramuscular group (306 ± 118 pg/ml; n = 15) at 2 months (P < 0.001). The difference was even greater at 4 months (1005 ± 595 versus 325 ± 165 pg/ml; P < 0.0005). Serum methylmalonic acid concentrations decreased to <3 SD above the normal range in all participants except one in the oral and two in the intramuscular group. Mean concentrations of the metabolites were not significantly different between the oral and the intramuscular groups, except at 4 months, when the value was higher in the intramuscular group (P < 0.05). Elevated serum total homocysteine decreased to 3 SD above the normal range in most participants, but the decrease was over 4 months in the oral group and during the first month in the 12 (n = 26) and in those receiving intramuscular vitamin B 12 (n = 34) for 90 days. The authors reported a statistically significant difference between day 0 and day 90 within both groups (P < 0.001) but did not analyse differences between both groups. Participants receiving oral and intramuscular vitamin B 12 improved in terms of cognitive function, sensory neuropathy and vibration sense and differences between both groups were not statistically significant.
We did not perform a meta-analysis because of differences in inclusion criteria, dose of oral vitamin B 12 and replacement regimen, and follow-up period and outcome measures.
Discussion
This review identified limited evidence from RCTs that oral vitamin B 12 is an effective treatment for vitamin B 12 deficiency in the short term. Evidence for long-term effectiveness was not identified. High doses of oral vitamin B 12 (2000 mg) daily are as effective as the intramuscular administration 23 in obtaining short-term haematological and neurological responses in patients with vitamin B 12 deficiency. High doses of oral vitamin B 12 (1000 mg) initially daily and thereafter weekly and then monthly are also as effective as intramuscular vitamin B 12 . 22 This body of evidence has serious limitations as it includes only two open studies with relatively short follow-up periods (90 days and 4 months) and small number of participants (n = 38 and n = 70) with some attrition. In addition, there are methodological limitations to both studies. Kuzminski and colleagues 23 did not clearly describe the method of randomization. Intention to treat analysis was not performed or mentioned in either study. Meta-analysis was not appropriate.
Neither study was conducted in Primary Care where most vitamin B 12 -deficient patients are treated. Another factor affecting applicability to primary care settings is that the studies used different treatment regimes and strict and numerous exclusion criteria.
A crucial aspect our study addresses is whether or not patients with conditions that might cause malabsorption may be safely treated with oral vitamin B 12 in primary care. This was difficult to ascertain because in the trials numbers are small, follow-up short and trials did not include patients with common conditions that might interfere with absorption in In addition to the included RCTs, we also identified many non-randomized studies assessing the effectiveness of oral vitamin B 12 . These studies, dated from the early 50s to recently, were mainly 'before and after studies' and all the included participants with vitamin B 12 deficiency responded to oral vitamin B 12 replacement therapy in clinical and/or laboratory terms. However, it is not clear in most of these studies how many included patients suffered from conditions that may cause malabsorption. There is considerable experience in Sweden in using oral vitamin B 12 to treat vitamin B 12 deficiency, where satisfactory clinical experience of treating over 145 700 patient years has been described. 17 Once again, it is not clear whether this experience included important numbers of patients that were suffering from malabsorptive conditions. Many patients with mild, dietary B 12 deficiency may have been included in this body of evidence. However, given that there is RCT evidence for a satisfactory haematological, biochemical and clinical short-term response for oral B 12 replacement in some patients with conditions associated with malabsorption, and evidence for satisfactory response in large numbers of vitamin B 12 -deficient patients, oral vitamin B 12 replacement is probably a safe option for most patients with low serum vitamin B 12 levels. However, dietary enhancement may have the same effect in many of these patients. A further large, pragmatic trial in primary care is needed to determine whether oral vitamin B 12 is effective in patients with major common cases of malabsorption in primary care settings. In the meantime, for patients newly diagnosed with vitamin B 12 deficiency and who have an intact terminal ileum, an initial intramuscular dose of vitamin B 12 followed by a trial of oral replacement may be considered. However, given the long half-life of body stores of vitamin B 12 , this strategy might not be the most appropriate for identifying those who will not respond to oral replacement therapy. A reasonable alternative is to institute a trial of oral vitamin B 12 from the time of diagnosis, with careful laboratory and clinical assessments of response. Those not responding should be started on intramuscular treatment.
This change in clinical practice might benefit many patients in terms of fewer visits to health carers and reduced discomfort associated with injections. Nursing time would be freed up for treating other patients. However, adherence and monitoring will remain an important consideration, regardless of the route of administration.
Summary
Vitamin B 12 deficiency can cause anaemia and neurological complications. Vitamin B 12 is rarely prescribed in the oral form in most countries. Two randomized controlled studies were included in this review. The trials recruited a total of 108 participants and followed up 93 of these from 90 days to 4 months. The evidence derived from these limited studies suggests that high oral doses of B 12 (1000 and 2000 mg) could be as effective as intramuscular administration in achieving haematological and neurological responses.
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